Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders
Lithium has established itself as an effective prophylactic agent in mood disorders, but not all patients respond to lithium therapy. It is probable that genetic factors play a substantial role in determining the differences in response to lithium. The aim of this study was to investigate the associ...
Saved in:
Published in | The international journal of neuropsychopharmacology Vol. 1; no. 2; pp. 125 - 129 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
Cambridge University Press
01.12.1998
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Lithium has established itself as an effective prophylactic agent
in mood disorders, but not all patients respond
to lithium therapy. It is probable that genetic factors play a substantial
role in determining the differences in
response to lithium. The aim of this study was to investigate the association
between the dopamine receptor
D3 (DRD3) gene and prophylactic efficacy of lithium in mood disorders.
Fifty-five subjects affected by bipolar
(n=43) and major depressive (n=12) disorder were followed
prospectively for an average of 49 months and
were also typed for their DRD3 variant, using polymerase chain reaction
techniques. DRD3 variants were not
associated with lithium outcome. Consideration of possible stratification
effects, such as gender, polarity, family
history, age at onset or duration of lithium treatment, also did not reveal
any associations. DRD3 variants are
not, therefore, a major factor influencing the prophylactic efficacy of
lithium in mood disorders. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1461-1457 1469-5111 |
DOI: | 10.1017/S1461145798001230 |